Vectura Group Plc has given an undisclosed partner US rights to a generic version of a therapy for asthma and chronic obstructive pulmonary disease that is being developed for delivery in a dry powder inhaler. The upfront payment is $10 million.
Vectura Group Plc has given an undisclosed partner US rights to a generic version of a therapy for asthma and chronic obstructive pulmonary disease that is being developed for delivery in a dry powder inhaler. The upfront payment is $10 million.